Cargando…

Primary Hepatic Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders After Methotrexate Therapy

Prior reports described cases of lymphoproliferative diseases occurring after methotrexate (MTX) administration, which are called methotrexate-associated lymphoproliferative disorders (MTX-LPDs). It has become clear that these lymphoproliferative diseases also occur following treatment with other im...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatayama, Yasuki, Sugiyama, Harutoshi, Murakami, Daisuke, Oura, Hirotaka, Shima, Yukiko, Shirato, Miho, Nishino, Takayoshi, Nakazawa, Tadao, Suehiro, Kenichi, Arai, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482596/
https://www.ncbi.nlm.nih.gov/pubmed/37692367
http://dx.doi.org/10.14740/jmc4135
_version_ 1785102205319118848
author Hatayama, Yasuki
Sugiyama, Harutoshi
Murakami, Daisuke
Oura, Hirotaka
Shima, Yukiko
Shirato, Miho
Nishino, Takayoshi
Nakazawa, Tadao
Suehiro, Kenichi
Arai, Makoto
author_facet Hatayama, Yasuki
Sugiyama, Harutoshi
Murakami, Daisuke
Oura, Hirotaka
Shima, Yukiko
Shirato, Miho
Nishino, Takayoshi
Nakazawa, Tadao
Suehiro, Kenichi
Arai, Makoto
author_sort Hatayama, Yasuki
collection PubMed
description Prior reports described cases of lymphoproliferative diseases occurring after methotrexate (MTX) administration, which are called methotrexate-associated lymphoproliferative disorders (MTX-LPDs). It has become clear that these lymphoproliferative diseases also occur following treatment with other immunosuppressive drugs, and they have been termed as other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPDs). In most of these cases, the duration of immunosuppressive drugs is very long, on the order of years. In the present study, we evaluated the development of lymphoproliferative disease despite the short duration of immunosuppressive treatment and determined the tumor doubling time. A 71-year-old woman was diagnosed with adult-onset Still’s disease. The patient was administered prednisone 30 mg per day starting on February 25, 2022 and MTX 6 mg per week starting 2 weeks later. Because she was a hepatitis B virus (HBV) carrier, nucleic acid analog therapy was also started to prevent HBV activation. Eight weeks later, biweekly tocilizumab was started. After 5 months of MTX administration, a solitary liver tumor measuring 37 × 32 mm(2) was detected. Three months later, repeat computed tomography revealed that the liver tumor had grown rapidly to 7 cm in diameter. We considered the possibility of OIIA-LPDs and stopped MTX therapy. Biopsy specimens of the liver tumor exhibited lymphocyte proliferation, which was consistent with OIIA-LPDs. The doubling time for tumor growth was 33 days. Despite withdrawing MTX for 6 weeks, the tumor continued to grow, and thus, the patient was referred to the hematology unit. In previously reported cases of MTX-LPDs of hepatic origin, the average duration of MTX administration was 7.3 (2 - 13) years. This report describes a primary hepatic OIIA-LPDs-associated tumor that rapidly increased in size after an extremely short period of MTX administration.
format Online
Article
Text
id pubmed-10482596
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-104825962023-09-08 Primary Hepatic Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders After Methotrexate Therapy Hatayama, Yasuki Sugiyama, Harutoshi Murakami, Daisuke Oura, Hirotaka Shima, Yukiko Shirato, Miho Nishino, Takayoshi Nakazawa, Tadao Suehiro, Kenichi Arai, Makoto J Med Cases Case Report Prior reports described cases of lymphoproliferative diseases occurring after methotrexate (MTX) administration, which are called methotrexate-associated lymphoproliferative disorders (MTX-LPDs). It has become clear that these lymphoproliferative diseases also occur following treatment with other immunosuppressive drugs, and they have been termed as other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPDs). In most of these cases, the duration of immunosuppressive drugs is very long, on the order of years. In the present study, we evaluated the development of lymphoproliferative disease despite the short duration of immunosuppressive treatment and determined the tumor doubling time. A 71-year-old woman was diagnosed with adult-onset Still’s disease. The patient was administered prednisone 30 mg per day starting on February 25, 2022 and MTX 6 mg per week starting 2 weeks later. Because she was a hepatitis B virus (HBV) carrier, nucleic acid analog therapy was also started to prevent HBV activation. Eight weeks later, biweekly tocilizumab was started. After 5 months of MTX administration, a solitary liver tumor measuring 37 × 32 mm(2) was detected. Three months later, repeat computed tomography revealed that the liver tumor had grown rapidly to 7 cm in diameter. We considered the possibility of OIIA-LPDs and stopped MTX therapy. Biopsy specimens of the liver tumor exhibited lymphocyte proliferation, which was consistent with OIIA-LPDs. The doubling time for tumor growth was 33 days. Despite withdrawing MTX for 6 weeks, the tumor continued to grow, and thus, the patient was referred to the hematology unit. In previously reported cases of MTX-LPDs of hepatic origin, the average duration of MTX administration was 7.3 (2 - 13) years. This report describes a primary hepatic OIIA-LPDs-associated tumor that rapidly increased in size after an extremely short period of MTX administration. Elmer Press 2023-08 2023-08-28 /pmc/articles/PMC10482596/ /pubmed/37692367 http://dx.doi.org/10.14740/jmc4135 Text en Copyright 2023, Hatayama et al. https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Hatayama, Yasuki
Sugiyama, Harutoshi
Murakami, Daisuke
Oura, Hirotaka
Shima, Yukiko
Shirato, Miho
Nishino, Takayoshi
Nakazawa, Tadao
Suehiro, Kenichi
Arai, Makoto
Primary Hepatic Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders After Methotrexate Therapy
title Primary Hepatic Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders After Methotrexate Therapy
title_full Primary Hepatic Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders After Methotrexate Therapy
title_fullStr Primary Hepatic Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders After Methotrexate Therapy
title_full_unstemmed Primary Hepatic Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders After Methotrexate Therapy
title_short Primary Hepatic Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders After Methotrexate Therapy
title_sort primary hepatic other iatrogenic immunodeficiency-associated lymphoproliferative disorders after methotrexate therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482596/
https://www.ncbi.nlm.nih.gov/pubmed/37692367
http://dx.doi.org/10.14740/jmc4135
work_keys_str_mv AT hatayamayasuki primaryhepaticotheriatrogenicimmunodeficiencyassociatedlymphoproliferativedisordersaftermethotrexatetherapy
AT sugiyamaharutoshi primaryhepaticotheriatrogenicimmunodeficiencyassociatedlymphoproliferativedisordersaftermethotrexatetherapy
AT murakamidaisuke primaryhepaticotheriatrogenicimmunodeficiencyassociatedlymphoproliferativedisordersaftermethotrexatetherapy
AT ourahirotaka primaryhepaticotheriatrogenicimmunodeficiencyassociatedlymphoproliferativedisordersaftermethotrexatetherapy
AT shimayukiko primaryhepaticotheriatrogenicimmunodeficiencyassociatedlymphoproliferativedisordersaftermethotrexatetherapy
AT shiratomiho primaryhepaticotheriatrogenicimmunodeficiencyassociatedlymphoproliferativedisordersaftermethotrexatetherapy
AT nishinotakayoshi primaryhepaticotheriatrogenicimmunodeficiencyassociatedlymphoproliferativedisordersaftermethotrexatetherapy
AT nakazawatadao primaryhepaticotheriatrogenicimmunodeficiencyassociatedlymphoproliferativedisordersaftermethotrexatetherapy
AT suehirokenichi primaryhepaticotheriatrogenicimmunodeficiencyassociatedlymphoproliferativedisordersaftermethotrexatetherapy
AT araimakoto primaryhepaticotheriatrogenicimmunodeficiencyassociatedlymphoproliferativedisordersaftermethotrexatetherapy